A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia

Suchonwanit, Poonkiat; Srisuwanwattana, Ploychompoo; Chalermroj, N.; Khunkhet, Saranya

doi:10.1111/jdv.15171

Cited by 80 publications

(74 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies performed on Asians reported a lower prevalence of AGA and FPHL compared with the Europeans. [49][50][51][52] The development of AGA in Japanese men is approximately 10 years slower than that in Europeans, with 1.4-times lower in prevalence in each decade. 51 By contrast, the prevalence of AGA in Thais is higher and relatively similar to Caucasians, suggesting that the prevalence may be influenced by various genetic backgrounds.…”

Section: Non-scarring Alopecias In Asiansmentioning

confidence: 99%

<p>Asian Hair: A Review of Structures, Properties, and Distinctive Disorders</p>

Leerunyakul¹,

Suchonwanit²

2020

CCID

View full text Add to dashboard Cite

Asian hair is known for its straightness, dark pigmentation, and large diameter. The cuticle layer in Asians is thicker with more compact cuticle cells than that in Caucasians. Asian hair generally exhibits the strongest mechanical properties, and its cross-sectional area is determined greatly by genetic variations, particularly from the ectodysplasin A receptor gene. However, knowledge on Asian hair remains unclear with limited studies. This article aimed to review and summarize the characteristics and properties of Asian hair. It also aimed to discuss hair disorders including linear lupus panniculitis and pseudocyst of the scalp that occur distinctively in Asian populations.

show abstract

Section: Non-scarring Alopecias In Asiansmentioning

confidence: 99%

<p>Asian Hair: A Review of Structures, Properties, and Distinctive Disorders</p>

Leerunyakul¹,

Suchonwanit²

2020

CCID

View full text Add to dashboard Cite

show abstract

“…The effect of a topical solution of 0.25% finasteride on scalp dihydrotestosterone (DHT) in men with AGA suggested that sexual side‐effects would be minimized compared with oral finasteride . A topical solution of 0.25% finasteride admixed with 3% minoxidil tested in 40 men with AGA was reported to be significantly superior to minoxidil alone in improving hair density, hair diameter and global photographic assessment . About 90% of patients treated with the combined solution experienced moderate to marked improvement with minimal effect on plasma DHT levels and no systemic adverse events.…”

Section: Key Issues In Hair Loss: From Physiology To Treatmentmentioning

confidence: 99%

Dermatology today and tomorrow: from symptom control to targeted therapy

Blume-Peytavi

Bagot

Tennstedt

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

For many decades and until recently, medical approach to dermatologic diseases has been based on the physician's ability to recognize and treat symptoms. Nowadays, advances in the understanding of the biology of diseases and in technologies for intervening against them have allowed physicians to diagnose and treat underlying disease processes rather than simply addressing the symptoms. This means that rather than addressing ‘the disease in humans’, physicians can now address the particular pathologic (biologic, molecular) disturbance as it presents in the individual patient, i.e., physicians now can practice something much closer to ‘personalized medicine’, leading to greater benefits for the patients and the health of society in general. The deeper understanding of ultraviolet radiation, the importance of photoprotection and increased knowledge about signalling pathways of melanoma and carcinoma have led to more complete care for the dermatologic patient. The current popularity for excessive exposure to the sun, without adequate application of the appropriate photoprotection remedies, is the origin of melanoma, but also for the weakening of the structure and functions of the skin. Indeed, fragility of the skin can affect humans around the world. In the senior population, this skin fragility is accompanied by pruritus, whereas atopic dermatitis is an inflammatory disease with highest prevalence in children and adolescents. Acne, the number one reason for dermatologic consultations worldwide, increases its prevalence in adolescents and in females. Senescent alopecia affects humans after menopause and andropause. The articles in this publication present an overview of the current advanced understanding of the diagnosis and therapeutic approaches in 6 fields of dermatology – dermatopaediatry and gerontodermatology, oncodermatology, hair loss, atopic dermatitis, photoprotection and acne – and thereby serve as a useful compendium of updated information and references for all healthcare professionals who see patients with presentations of the symptoms of these diseases.

show abstract

“…Although the exact molecular mechanisms are not fully understood, an abnormal level of dihydrotestosterone (DHT), a potent androgen, appears to be an important causative factor 1,2. Indeed, the upregulation of the 5α‐reductase enzyme is required to convert testosterone into DHT and is a drug target 3,4…”

Section: Introductionmentioning

confidence: 99%

“…Currently, only two treatments have been approved by the US Food and Drug Administration for the treatment of male AGA5: finasteride, a 5α‐reductase inhibitor3,6,7 administrated at 1 mg daily, and topical minoxidil (MXD) formulations (2% solution, 5% solution, or 5% foam). The effectiveness of both drugs in improving the symptoms of the disease has been demonstrated in several well‐designed studies 8,9.…”

Section: Introductionmentioning

confidence: 99%

The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia

Maqoud

Zizzo

Mele

et al. 2020

Pharmacology Res & Perspec

View full text Add to dashboard Cite

The efficacy of minoxidil (MXD) ethanolic solutions (1%‐5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions. The toxicological effects of repeated topical applications of escalating dose (0.035%‐3.5% w/v) and of single and twice daily doses (3.5% w/v) of a novel hydroxypropyl‐β‐cyclodextrin MXD GEL formulation (MXD/HP‐β‐CD) and a MXD solution were investigated in male rats. The cardiovascular effects were evaluated by telemetric monitoring of ECG and arterial pressure in free‐moving rats. Ultrasonographic evaluation of cardiac morphology and function, and histopathological and biochemical analysis of the tissues, were performed. A pharmacovigilance investigation was undertaken using the EudraVigilance database for the evaluation of the potential cancer‐related effects of topical MXD. Following the application of repeated escalating doses of MXD solution, cardiac hypertrophy, hypotension, enhanced serum natriuretic peptides and K+‐ion levels, serum liver biomarkers, and histological lesions including renal cancer were observed. In addition, the administration of a twice daily dose of MXD solution, at SF rat vs human = 311, caused reductions in the systolic, diastolic, and mean blood pressure of the rats (−30.76 ± 3%, −28.84 ± 4%, and −30.66 ± 5%, respectively, vs the baseline; t test P < .05). These effects were not reversible following washout of the MXD solution. Retrospective investigation showed 32 cases of cancer associated with the use of topical MXD in humans. The rats treated with MXD HP‐β‐CD were less severely affected. MXD causes proliferative adverse effects. The MXD HP‐β‐CD inclusion complex reduces these adverse effects.

show abstract

A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia

Abstract: Treatment with topical solution of 0.25% finasteride admixed with 3% minoxidil was significantly superior to 3% minoxidil solution for promoting hair growth in male androgenetic alopecia, and well tolerated.

Cited by 80 publications

References 27 publications

<p>Asian Hair: A Review of Structures, Properties, and Distinctive Disorders</p>

<p>Asian Hair: A Review of Structures, Properties, and Distinctive Disorders</p>

Dermatology today and tomorrow: from symptom control to targeted therapy

The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia

Contact Info

Product

Resources

About